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Summary
Background: Early coronavirus disease 2019 (COVID-19) diagnosis prior to laboratory testing results is crucial for infection
control in hospitals. Models exist predicting COVID-19 diagnosis, but significant concerns exist regarding methodology and
generalizability.
Aim: To generate the first COVID-19 diagnosis risk score for use at the time of hospital admission using the TRIPOD (trans-
parent reporting of a multivariable prediction model for individual prognosis or diagnosis) checklist.
Design: A multivariable diagnostic prediction model for COVID-19 using the TRIPOD checklist applied to a large single-
centre retrospective observational study of patients with suspected COVID-19.
Methods: 581 individuals were admitted with suspected COVID-19; the majority had laboratory-confirmed COVID-19 (420/
581, 72.2%). Retrospective collection was performed of electronic clinical records and pathology data.
Results: The final multivariable model demonstrated AUC 0.8535 (95% confidence interval 0.8121–0.8950). The final model
used six clinical variables that are routinely available in most low and high-resource settings. Using a cut-off of 2, the
derived risk score has a sensitivity of 78.1% and specificity of 86.8%. At COVID-19 prevalence of 10% the model has a nega-
tive predictive value (NPV) of 96.5%.
Conclusions: Our risk score is intended for diagnosis of COVID-19 in individuals admitted to hospital with suspected
COVID-19. The score is the first developed for COVID-19 diagnosis using the TRIPOD checklist. It may be effective as a tool to
rule out COVID-19 and function at different pandemic phases of variable COVID-19 prevalence. The simple score could be
used by any healthcare worker to support hospital infection control prior to laboratory testing results.
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Introduction
Coronavirus disease 2019 (COVID-19) is a potentially life-
threatening acute respiratory infection caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2).1 The virus,
originally identified in Wuhan, China, is responsible for pan-
demic disease and unprecedented global pressures on acute
hospital services.2 Pneumonia appears to be the most common
presentation of COVID-19 although a range of non-respiratory
symptoms are common.3,4 Hospitalization rates for individuals
with COVID-19 increase with age, up to approximately 18%.5
Prompt diagnosis of COVID-19 at admission is fundamental
to acute management, infection control and prevention of noso-
comial transmission.6 Worldwide, secondary care isolation
facilities have been saturated meaning that patients admitted
to hospital must frequently be cohorted in shared ward spaces.7
Inappropriate cohorting of patients with and without COVID-19
risks nosocomial transmission. The current gold standard for
diagnosis of acute COVID-19 remains laboratory-based PCR test-
ing of respiratory samples, most commonly swabs from the
upper respiratory tract (URT).8,9 Even in high-resource settings,
the turnaround time from sampling to result is often more than
24 h, and testing of URT samples has a recognized false-
negative rate.10,11 COVID-19 management and infection control
decisions at admission are therefore founded on routinely avail-
able investigations and clinical judgement.
A number of diagnostic prediction models are available for
COVID-19; however, systematic review suggested that none are
suitable for clinical use.12 In particular, no model has been
derived from a real-world population of individuals with sus-
pected COVID-19 who require admission to hospital. Our diag-
nostic prediction model is intended for use by acute hospital
staff to support clinical diagnosis of individuals with COVID-19
to guide infection control decisions within the first 24 h of ad-
mission in the absence of laboratory testing for SARS-CoV-2. We
used TRIPOD (Transparent Reporting of a multivariable predic-
tion model for Individual Prognosis Or Diagnosis) to develop
and validate our model using routinely available data from a co-




Participants included in this study, which was conducted in an
east London hospital, were identified from a pathology database
of all respiratory specimens sent for laboratory SARS-CoV-2 PCR
testing between 16 March and 12 April 2020 (inclusive). The
electronic records of all adults (aged >18 years) identified from
this database were then interrogated to identify those individu-
als who were admitted to secondary care. Adults tested in ma-
ternity services were excluded as the department did not
adhere to national COVID-19 testing guidelines at that time.13
Patients who received COVID-19 testing more than 72 h after ad-
mission were also excluded given the small possibility positive
tests results represented nosocomial infection. Admission to
secondary care was defined as hospital inpatient stay exceeding
24 h. Therefore, by definition all participants included in the
analysis are patients with suspected COVID-19 consistent with
national guidelines who received laboratory SARS-CoV-2 testing
at least once within 72 h of admission.13
Source of data
Retrospective collection was undertaken of all routinely avail-
able clinical observations and blood test results at time of ad-
mission from Clinical Records Service Millennium electronic
patient records. Nadir observations were selected as the least
physiologically favourable measurement at any time prior to
time of patient arrival on an inpatient ward. Admission chest
radiography reports by consultant radiologists were classified
according to the British Institute of Radiology and British
Society of Thoracic Imaging templates: normal, suggestive of
COVID-19, indeterminate for COVID-19, suggestive of alterna-
tive diagnosis.14 Local guidelines actively discouraged use of CT
imaging at this time and we did not collect these data. All
results of laboratory SARS-CoV-2 PCR testing of respiratory sam-
ples for each individual were recorded. At the time of this study,
there was no local guidance regarding the number of samples
that should be sent from individual patients after an initial
negative result. Retrospective electronic notes audit was under-
taken to establish history of fever, duration of symptoms and
final clinical diagnosis at 30 days post admission.
Outcome
Our outcome was defined as either respiratory sample positive
for SARS-Cov2 (on either the admission sample or on a subse-
quent swab taken within 72 h of admission) OR a clinical diag-
nosis of COVID-19. A clinical diagnosis was defined by a senior
clinician (a consultant) formally documenting a diagnosis of
COVID-19 in electronic records in the absence of a positive
SARS-CoV-2 laboratory test. A clinical diagnosis of COVID-19
was ascertained from a retrospective review of the electronic
notes undertaken at discharge or death, or during the admis-
sion if still an inpatient at 30 days.
Predictors
As a group, authors prioritized a minimum number of predic-
tors that the model should contain to enhance implementation
in the clinical setting weighed against the effective sample size
(see below). Decisions about which predictors to retain in the
final model were therefore based primarily on clinical reasoning
and availability of predictor measurement at the time the model
would be used (within 24 h of admission).
We included age as it is independently associated with se-
verity of symptoms resulting from COVID-19 infection, and we
reasoned that the likelihood of hospital admission with sus-
pected COVID-19 increases with age. We created a composite
variable for fever to encompass history of fever (subjective
reporting at any time during acute illness) and any documented
fever 37.8C. We reasoned that this composite would be more
sensitive to capture fever as a feature of COVID-19, in particular
in the presence of anti-pyretic therapy. Hypoxemic respiratory
failure, in the absence of other clinical features, is increasingly
recognized as a common presentation of COVID-19 pneumo-
nia.15,16 We decided a priori to use either maximal FiO2 require-
ments within the first 24 h of admission or lowest recorded O2
saturations rather than any respiratory symptoms, e.g. short-
ness of breath or cough. On examination of the data, FiO2 was
used in preference to O2 saturations as there was a wider range
of values with FiO2 (see Supplementary Data Section). We also
decided a priori that heart rate and respiratory rate will have
limited discriminatory power with regards to diagnostic predic-
tion model for acutely unwell adults. We also included chest
radiograph findings which are commonly used by clinicians to
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investigate any respiratory or febrile illness. We reasoned that
most clinicians are able to distinguish a normal chest X-ray
from one that is non-specifically abnormal or indeterminate so
created a binary category.
C-reactive protein (CRP) rises in both viral and bacterial
causes of acute respiratory illness with some literature suggest-
ing that on average CRP level is higher in the bacterial causes of
community-acquired pneumonia than viral causes. Conversely,
the lack of a rise in neutrophil count has been shown to correl-
ate well with viral causes.15,17 We therefore decided a priori that
CRP and neutrophil count should both be included in the model.
On examination of the data distribution of the predictors, neu-
trophil count was also found to have a wider range (as com-
pared to lymphocytes or neutrophil to lymphocyte ratio). We
did not include absolute lymphocyte counts as a variable owing
to the narrow distribution of data which would be expected to
have poor discriminatory function (see Supplementary data).
Predictors which had many missing values and were therefore
excluded were Troponin T (49.5% missing), lactate dehydrogen-
ase (LDH, 67.6% missing), ferritin (43.3%) and D-dimer (50.7%).
Our choice of predictors was therefore not based on poten-
tially biased univariable selection of predictors. Predictors
examined during modelling included: age, fever (history of fever
OR any documented fever 37.8C within 24 h), CXR (chest
X-ray) finding (normal or abnormal/indeterminate), maximal
oxygen requirements during first 24 h of admission, lowest
recorded oxygen saturations, CRP, neutrophil count, neutrophils
to lymphocyte ratio and highest temperature recorded during
first 24 h. For the continuous predictors, e.g. age, CRP, neutro-
phil count, a linear relationship with the outcome was modelled
after assessment of non-linearity.
Sample size
All available data were used to maximize the power and gener-
alizability of the results. The sample size was determined by
the availability of existing data at the time and not statistical
considerations. The well-known rule of thumb for sample size
for prediction models is to have at least 10 events per variable
(EPV) although this has been called into question recently.18
For binary outcomes, the number of events is the number of
cases in the smallest of the two outcome levels so for this ana-
lysis, that equates to 90 events. We therefore a priori decided to
restrict the number of variables in the final prediction model
to 6 (15 EPV).
Model development, calibration and internal validation
Multivariable logistic regression sequentially removing the vari-
able with the largest Wald P values >0.05 (stepwise backward
elimination) was undertaken to generate our final model. A
complete case analysis was conducted, excluding participants
with missing information relating to any of the predictors.
Calibration and discrimination
We assessed model calibration, the agreement between prob-
ability of COVID-19 predicted by the model and observed prob-
ability of COVID-19 within quantiles of predicted risk,
graphically in a calibration plot and statistically using the
Hosmer–Lemeshow goodness-of-fit test.19 We then assessed
discrimination, the ability of our model to differentiate patients
with COVID-19 from those without using the area under the
receiver-operating characteristic curve (AUC).
Internal model validation
The bootstrap procedure was employed for internal valid-
ation.20 The predictor selection was applied to each bootstrap
sample to obtain a final model, and the optimism was esti-
mated by comparing the final model performance to the origin-
al data for each bootstrap sample (n¼ 200). The bootstrap
corrected area under the curve was computed by subtracting
the optimism from the original area under the curve.
Transformation from regression model to risk score
We used the beta coefficients and intercept from the final re-
gression model, generated from the complete dataset, to calcu-
late the risk score for each participant. We then used the risk
score to create a cut-off threshold to identify ‘high risk COVID-
19’ versus ‘low risk COVID-19’ patients and calculated sensitiv-
ity, specificity, negative and positive predictive values for each
cut-off. The negative predictive value (NPV) and positive pre-
dictive value (PPV) were then calculated for each cut-off thresh-
old for varying prevalence of COVID-19 in the study population.
All statistical analyses were performed using STATA/SE 16
(Stata Corporation, College Station, USA).
Study approval
The study was reviewed by the Joint Research Management
Office for Barts Health NHS Trust and Queen Mary University of
London. The UK Government Coronavirus Act provides for hos-
pitals to utilize anonymised routinely collected health data as
part of the response to the COVID-19 pandemic and ethical ap-
proval was therefore not required.
Results
Patient characteristics
Between 16 March and 12 April, 985 individuals were tested for
SARS CoV-2 at our hospital. Five hundred and eighty-one
patients, who were admitted to hospital with suspected COVID-
19, were included for analysis (Figure 1). Most participants were
diagnosed with confirmed or probable COVID-19 (491/581,
84.5%; Table 1); the majority had COVID-19 confirmed by labora-
tory testing (420/581, 72.2%) and most positive results were con-
firmed on the first respiratory specimen tested (381/420, 90.7%).
The median age of the study population was 67 years (range
19 101) and 58.7% were male (Table 1). For individuals with data
available, the median duration of symptoms prior to admission
was 7 days (n¼ 499; range 0.32). Observation variables and a full
blood count were available for all patients at the time of admis-
sion. Chest radiographs were not performed at admission in 9
(1.6%) and CRP was missing for 12 patients (2.1%).
Diagnostic model and performance measures
The development of this model was primarily guided a priori by
clinical reasoning as outlined in methods. Our final model com-
prised of age (continuous, linear), neutrophil count (continuous,
linear), CRP (continuous, linear), maximal FiO2 requirements
(continuous, linear), documented or reported fever (yes¼ 1,
no¼ 0) and chest X-ray findings (normal¼ 1, not normal [includ-
ing indeterminate]¼ 0). There was very little missing data for
the predictors included in the final model. Only 21 (3.6%)
patients were dropped from the complete case analysis. The
final multivariate model is show in Table 2 (regression
coefficients).
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Internal validation
The final multivariable model demonstrated adequate calibra-
tion and discrimination with Hosmer–Lemeshow statistic
P¼ 0.41 and AUC 0.8535 (95% confidence interval [0.8121–
0.8950]). The AUC and calibration plots are shown in Figure 2
and Supplementary Figure E1, respectively. The optimism-
corrected AUC was 0.8465 (95% CI 0.7814–0.9038). The model
performed comparably well for patients aged less than 80 years
(AUC 0.8736, 95% confidence interval 0.8291–0.9181) and greater
than 80 years (AUC 0.8364, 95% confidence interval 0.7492–
0.9236).
Risk scores
The risk scores were rounded to the nearest integer and Table 3
shows the proportion of patients diagnosed with COVID-19 at
each value of the rounded risk score. A histogram of the risk
scores is shown in Supplementary Figure E2. Using a cut-off
threshold of 2 for the risk score, the diagnostic prediction model
has a sensitivity of 78.1% and specificity of 86.8%. At COVID-19
prevalence of 85%, the diagnostic prediction model has a PPV of
95.1% and NPV of 36.0% (Supplementary Table E1). At COVID-19
prevalence of 10%, the PPV falls to 28.1% and NPV rises to 96.5%
(Supplementary Table E1).
Discussion
Our retrospective cross-sectional study is the first to derive a
COVID-19 diagnostic prediction model intended to support in-
fection control decision making at the time of hospital admis-
sion in the absence of laboratory testing. To our knowledge, we
have also derived and internally validated the first COVID-19
diagnostic prediction model that applies the TRIPOD checklist
for prediction model development.21 Our model performs well
in predicting COVID-19 diagnosis at times of high COVID-19
prevalence, such as during the period of data collection for this
study (AUC¼ 0.8535). Crucially, extrapolated from our data, the
model demonstrates a high NPV when applied to populations
with lower COVID-19 prevalence which may speak to its utility
as a rule-out tool for COVID-19 at other phases of the pandemic
(NPV¼ 93.7%). Our prediction tool may also help guide clinician
decision making about whether repeat SARS-CoV-2 testing is
warranted following an initial negative test. We would have
liked to attempt external validation of other published COVID-
19 diagnostic prediction models purposed for COVID-19 infec-
tion control but found only one related article that has not been
peer-reviewed and did not generate a prediction model.22
Strengths and limitations
Multiple other diagnostic prediction models, derived from dif-
ferent populations and clinical scenarios, are published or in
pre-print, however there is significant concern regarding the
rigour of model development and their real-world utility.12 Our
diagnostic prediction model is a cross-sectional study based on
participants selected on the basis of symptoms or signs suggest-
ive of the condition of interest (COVID-19) which should intrin-
sically minimize risk of bias. Selection of predictors is a point of
controversy consistently raised in commentaries relating to
prediction modelling.23 There is no formal consensus regarding
the best method for selecting predictors for such models but
suggested approaches include literature review, clinical experi-
ence and statistical selection of variables, all of which informed
our model.12,20,24,25 Given the risk of bias associated with uni-
variate analyses to select predictors, we analysed data distribu-
tion to select predictors with high likelihood of discriminatory
function (Supplementary Figures E3–E4; Supplementary Table
E2). We also prioritized clinical availability of measurements in
our predictor selection. All of our model predictors should be
routinely available in all healthcare settings, including those of
low-resource. Further, the use of investigation results in the
model has also been intentionally designed for simple use by a
Figure 1. Participant flow.
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non-specialist healthcare worker, including those unfamiliar
with COVID-19. In particular, the predictor of chest radiography
findings has been dichotomized to normal or abnormal for the
final risk score which requires very little familiarity with
COVID-19 imaging or indeed chest radiography generally.
Specialist and non-routine investigations, such as lung ultra-
sound, used in other COVID-19 diagnosis prediction studies,
were also purposefully not assessed in this study.26 An alterna-
tive diagnosis to COVID-19, as determined by the admitting
team, was not assessed as a predictor given inherent complex-
ity and subjectivity as a parameter, and given the retrospective
design of the study.
One important limitation of our study is that data collection
was undertaken at approximately the time of peak prevalence
of COVID-19 in the UK. The model is therefore likely to be over-
optimistic in predicting COVID-19 disease. However, our simple
model can be easily tested in different settings. The small pro-
portion of participants diagnosed with probable COVID-19,
within the composite COVID-19 diagnosis outcome, might be
expected to introduce bias given that the clinical diagnosis of
probable COVID-19 would not have been blinded to the same
predictors used in our model. However, the model performed
comparably whether outcomes encompassed confirmed
COVID-19 cases alone or a composite of confirmed and probable
COVID-19 cases (data not shown). It is also important to note
that prevalence of other respiratory viruses (such as influenza)
was low in this population at this time (3 respiratory specimens
tested positive for non-SARS-CoV-2 pathogens out of 115
requested). Our predictors may not prove to be highly specific
for COVID-19 as compared with infections caused by other re-
spiratory viruses. However, the same principles of early identifi-
cation and infection control apply to any viral respiratory
illness. It will be instructive to validate the model during winter
seasons when we might traditionally expect higher prevalence
of other seasonal respiratory viruses compared to SARS-CoV-
2.27 However, COVID-19-related changes to global travel and
public health may significantly disrupt future global patterns of
respiratory virus seasonality and prevalence.
The study was conducted at a single site but is expected to
be representative of UK and western European acute hospital
settings, and urban UK and western European patient popula-
tions. The study was designed to predict COVID-19 diagnosis in
individuals presenting with syndromes consistent with sus-
pected COVID-19. Our definition of suspected COVID-19 was
derived from national guidelines which emphasize testing in
patients presenting with acute respiratory or influenza-like ill-
nesses.13 Our study was conducted prior to formal addition of
anosmia or dysgeusia as symptoms that indicate COVID-19 la-
boratory testing. We would expect most patients requiring hos-
pitalization would have other symptoms besides these
relatively minor complications. However, our study may have
missed individuals with atypical presentations of COVID-19,
such as delirium in elderly patients, which are not included in
national COVID-19 testing guidelines as clinical syndromes
indicating SARS-CoV-2 laboratory testing.28 Our data suggest
that diagnosis of COVID-19 in elderly populations, particularly
those aged over 80 years, with respiratory or influenza-like
symptoms is comparable to younger populations. Diagnostic
prediction models aimed at elderly populations and other
Table 2. Regression coefficients from the final prediction model
Coefficient Standard error z P> z 95% Confidence Interval
Age 0.0176018 0.0080696 2.18 0.029 0.0017857 0.0334179
Fever 1.547593 0.2931327 5.28 0.000 0.9730635 2.122122
Maximal FiO2 0.0223121 0.0075972 2.94 0.003 0.0074219 0.0372023
CRP 0.0045913 0.0016767 2.74 0.006 0.001305 0.0078776
Normal CXr 1.113497 0.2879424 3.87 0.000 1.677854 0.5491403
Neutrophils 0.1611107 0.0321778 5.01 0.000 0.2241779 0.0980434
Intercept 0.0367507 0.6817362 0.05 0.957 1.372929 1.299428
FiO2, maximal fraction of inspired oxygen in the first 24 h of admission; CXr, chest X-ray.
Table 1. Patient characteristics
Characteristics n (col %)
Age at admission (years): median (IQR) 67 (19–101)
Male 341 (58.7)
Time between symptom onset and admission
(days): median (IQR) (n¼ 499)
7 (3–10)
History of fever or documented fever in the first
24 h from admission
420 (72.3)
Observations in the first 24 h from admission:
median (IQR)
Highest temperature 38.0 (37.3–38.6)
Lowest O2 saturations 93 (90–95)
Highest FiO2 0.36 (0.24–0.60)
Highest respiratory rate 27 (22–32)
Highest heart rate 104 (93–115)
Lowest systolic blood pressure 107 (99–117)
Chest X-ray at admission
Normal 122 (21.0)
Suggestive of COVID-19 303 (52.1)
Indeterminate 103 (17.7)
Alternative diagnosis 44 (7.6)
Not done 9 (1.6)
Blood tests on admission: median (IQR)
CRP, mg/L (n¼ 569) 92 (46–167)
Neutrophils, 109 cells/L 6.4 (4.6–9.2)
Lymphocytes, 109 cells/L 1.0 (0.7–1.4)
ALT, U/L (n¼ 494) 30 (20–52)
Ferritin, ng/ml (n¼ 366) 891 (430–1692)
LDH, U/L (n¼ 222) 400 (280–502)
Troponin T, ng/L (n¼ 335) 16 (7–42)
D-dimer, mcg/mL (n¼ 319) 1.0 (0.59–2.3)
SARS-CoV-2 detected by RT-PCR 420 (72.3)
SARS-CoV-2 detected by RT-PCR on first sample
(n¼ 381)
381 (90.7)
Clinical diagnosis of COVID-19 only 71 (12.2)
Outcome: either laboratory-confirmed or clinical
diagnosis
491 (84.5)
n, number; IQR, interquartile range; FiO2, fraction of inspired oxygen; CRP, C-re-
active protein; LDH, lactate dehydrogenase.
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sub-populations who might be expected to present with atyp-
ical or pauci-respiratory syndromes of COVID-19, such as im-
munocompromised patients, warrant dedicated study.
Implications
Necessarily, the wider utility of our model requires validation to
define its role in clinical practice. External validation of the
model is needed for similar populations requiring hospitalization
with suspected COVID-19 both inside and outside the UK.
Temporal validation of our model will be crucial to explore its
utility at different phases of the COVID-19 pandemic. While clin-
ical acumen and appropriate laboratory testing should dictate
management of COVID-19, if validation in a dataset where
COVID-19 prevalence is low does confirm the high NPV of our
model then it promises to be a useful tool to support decision-
making for patients with suspected COVID-19 at the time of ad-
mission to hospital. The model may serve to rule out COVID-19
in these patients and extricate them from respiratory isolation,
thus preserving infection control resources and patient safety. At
times of high prevalence of COVID-19, such as might be expected
during a second epidemic wave, our model will add little to the
diagnosis of individuals presenting with suspected COVID-19
when the pre-test probability is high. But during dynamic phases
of increasing and reducing incidence, the model, which is
dependent on cheap and widely available investigations, may
prove very useful in both high- and low-resource countries.
Supplementary material
Supplementary material is available at QJMED online.
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